

1 **TITLE**

2 Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a
3 symptomatic control group.

4

5 **AUTHORS**

6 ➤ Ana Beatriz C Cazé– ana.caze@ufba.br - Universidade Federal da Bahia, Salvador,
7 Bahia, Brazil

8 ➤ Thiago Cerqueira-Silva, MD - csilvathiago@hotmail.com - LIB and LEITV
9 Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil;
10 Universidade Federal da Bahia, Salvador, Bahia, Brazil

11 ➤ Adriele Pinheiro Bomfim, M. Sc., - adrielepbomfim@gmail.com – Instituto Gonçalo
12 Muniz, Fiocruz, Salvador, Brazil; Universidade Federal da Bahia, Salvador, Bahia,
13 Brazil

14 ➤ Gisley Lima de Souza - gisleysouza19.1@bahiana.edu.br - Escola de Medicina e
15 Saúde Pública da Bahia; Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil

16 ➤ Amanda Canário Andrade Azevedo, MD, M.Sc. – amandacanario@gmail.com -
17 Hospital Santa Izabel, Santa Casa da Bahia, Salvador, Bahia, Brazil

18 ➤ Michelle Queiroz Aguiar Brasil, MD, M. Sc. - michelleqas@gmail.com - Instituto
19 Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil; Federal University of Bahia,
20 Salvador, Bahia, Brazil

21 ➤ Nara Rúbia Santos - narabusiness@hotmail.com - Departamento de Vigilância em
22 Saúde/Vigilância Epidemiológica, Campo Formoso, Bahia Brazil

23 ➤ Ricardo Khouri, PhD - ricardo_khouri@hotmail.com - Department of Microbiology,
24 Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of

25 Clinical and Epidemiological Virology, Belgium; Instituto Gonçalo Moniz, Fiocruz,
26 Salvador, Bahia, Brazil

27 ➤ Jennifer Dan, MD, PhD – jd@ucsd.edu - Center for Infectious Disease and Vaccine
28 Research, la Jolla Institute for Immunology (LJI); Department of Medicine, Division
29 of Infectious Disease and Global Public Health, University of California, San Diego
30 (UCSD), La Jolla, CA 92037, USA

31 ➤ Antonio Carlos Bandeira, MD, PhD, – antoniobandeira@gmail.com - UNI-FTC-
32 Faculdade Tecnologia Ciências Medical School, Bahia; Central State Laboratory
33 LACEN-Bahia; Infectious Diseases Advisor

34 ➤ Luciano Pamplona de Goes Cavalcanti, MD, PhD - pamplona.luciano@gmail.com -
35 Universidade Federal do Ceará, Fortaleza, Ceará, Brazil; Centro Universitario
36 Christus, Fortaleza, Ceará, Brazil

37 ➤ Manoel Barral-Netto, MD, PhD - manoel.barral@fiocruz.br - LIB and LEITV
38 Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil;
39 Universidade Federal da Bahia, Salvador, Bahia, Brazil

40 ➤ Aldina Maria Prado Barral - aldina.barral@fiocruz.br - Instituto Gonçalo Moniz,
41 Fundação Oswaldo Cruz, Salvador, Bahia, Brazil; Instituto de Investigação em
42 Imunologia, São Paulo, São Paulo, Brazil

43 ➤ Cynara Gomes Barbosa*, PhD - cynara.barbosa@gmail.com - Universidade Federal
44 da Bahia, Salvador, Brazil

45 ➤ Viviane Sampaio Boaventura *, MD, PhD, - vsboaventura@gmail.com - LIB and
46 LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil;
47 Universidade Federal da Bahia, Salvador, Bahia, Brazil

48 *Those authors equally supervised this study

49 **Corresponding author**

50 Viviane Sampaio Boaventura

51 Email address: ysboaventura@gmail.com

52 Telephone: + 55 71 31762211

53 Postal address: 121 Waldemar Falcão Street, Candeal, Salvador, Bahia, Brazil, CEP 40296

54

55

56

57 **ABSTRACT**

58

59 *Background*

60 There is limited data on the prevalence and risk factors for long COVID, with a shortage of
61 prospective studies with appropriate control groups and adequate sample size. We therefore
62 performed a prospective study to determine the prevalence and risk factors for long COVID.

63 *Methods*

64 We recruited patients age ≥ 15 years who were clinically suspected of having acute SARS-
65 CoV-2 infection from September 2020 to April 2021. Nasopharyngeal swabs were collected
66 for RT-PCR 3-5 days post symptom onset. Clinical and sociodemographic characteristics
67 were collected using structured questionnaires from persons positive and negative for SARS-
68 COV-2. Follow-up was performed by telephone interview to assess early outcomes and
69 persistent symptoms. For COVID-19 cases, 5D-3L EuroQol questionnaire was used to assess
70 the impact of symptoms on quality of life.

71 *Results*

72 We followed 814 participants (412 COVID-19 positive and 402 COVID-19 negative persons)
73 of whom the majority (741 / 814) had mild symptoms. Both the COVID-19 positive and the
74 COVID-19 negative groups had similar sociodemographic and clinical characteristics, except
75 for the rate of hospitalization (15.8% vs 1.5%, respectively). One month after disease onset,
76 122 (29.6%) individuals reported residual symptoms in the COVID-19 positive group or the
77 long COVID group versus 24 (6%) individuals in the COVID-19 negative group. In the long
78 COVID group, fatigue, olfactory disorder, and myalgia were the most frequent symptoms
79 which occurred in the acute phase. Compared to recovered patients, female sex, older age and
80 having > 5 symptoms during the acute phase were risk factors for long COVID. Quality of
81 life was evaluated in 102 out of 122 cases of long COVID with 57 (55.9%) reporting an
82 impact in at least one dimension of the EuroQol 5D-3L questionnaire.

83 *Conclusion*

84 In this prospective study consisting predominantly of patients with mild disease, the
85 persistence of symptoms after acute disease was highly associated with long COVID-19
86 (29.6% vs 6% of COVID negative group). The risk factors for long COVID were older age,
87 female sex, and polysymptomatic acute disease.

88

89 **KEYWORDS**

90 COVID-19; SARS-CoV-2; long COVID; frequency; risk factor; outpatients; post-COVID
91 syndrome; persistent symptoms; post-Acute COVID Syndrome; PASC.

92

93

94 **BACKGROUND**

95 Long COVID has received less attention from the scientific community than acute
96 COVID-19, representing less than 2% of COVID-19 publications in PubMed Clinical
97 Queries, August 31, 2022). Several important aspects remain undefined such as its
98 prevalence. Long COVID has been reported to affect between 7.5% to 89% of patients [1, 2,
99 29, 30]. Most of these studies do not include well-matched controls which is important
100 because long COVID-symptoms are nonspecific and may be attributed to other factors such
101 as the physical and mental impact of having COVID-19 infection or hospitalization [3,4].
102 Prospective studies enrolling symptomatic individuals with and without confirmed COVID-
103 19 are necessary to better estimate the prevalence of long COVID and its associated risk
104 factors.

105 Long COVID is anticipated to have a large impact on the healthcare system [5].
106 Identifying risk factors for developing long COVID will help mitigate its impact. Some risk
107 factors have been suggested for long COVID; however, these studies consisted of previously
108 hospitalized patients [1] or were retrospective analyses from electronic health records of not
109 hospitalized patients (31). We therefore performed a longitudinal study of patients with
110 COVID-like symptoms who tested positive or negative for SARS-CoV-2 to assess the
111 prevalence and risk factors for long COVID and its impact on the quality of life.

112

113 **METHODS**

114 *Study population*

115 We recruited individuals age ≥ 15 years with clinical suspicion of acute SARS-CoV-2
116 infection in health care units from three municipalities of Bahia State-Brazil (Irecê, Campo
117 Formoso, and Lauro de Freitas). Individuals who had difficulty in reporting symptoms, those
118 who were > 20 days post symptom onset at the time of recruitment, or those who reported

119 SARS-CoV-2 re-infection were excluded. The study was conducted from September 2020 to
120 April 2021. The ancestral strain or gamma variant of SARS-CoV-2 was dominant in Brazil
121 from November 2020 to August 2021 (**Additional file 1: Fig S1-2**) [6].

122

123 *Exposure measurement*

124 All patients were tested for COVID-19 by nasopharyngeal RT-PCR. Only individuals
125 who had an RT-PCR in the first ten days of disease onset were considered eligible for the
126 follow-up. The Strengthening the Reporting of Observational Studies in Epidemiology
127 (STROBE) protocol was followed.

128

129 *Recruitment strategy and data collected*

130 Consecutive in-person recruitment included the application of a structured survey
131 (Questionnaire 1) using Research Electronic Data Capture (REDCap) software hosted by the
132 Gonçalo Moniz Institute (IGM/FIOCRUZ) in Bahia, Brazil. The following information was
133 collected: sociodemographic characteristics (age, gender, skin color, body mass index,
134 anthropometric data, municipality of residence), comorbidities (hypertension, diabetes, heart
135 disease, chronic lung disease, other), date of symptom onset, acute symptoms (fever,
136 myalgias, arthralgias, cough, shortness of breath, nasal congestion, sneezing, coryza, sore
137 throat, sinus pain, retroocular pain, ear pain, headache, chest pain, chest discomfort, rash,
138 abdominal pain, loss of appetite, vomiting, diarrhea (2 or more episodes in the last 24 hours),
139 weakness, fatigue, lightheadedness or fainting, loss of smell, and loss of taste).

140

141 *Follow-up and outcome measurement*

142 SARS-CoV-2 positive (COVID-19) and negative (non-COVID-19) patients who
143 reported COVID-like symptoms were followed. Negative cases were recruited on the same

144 day as positive cases before nasopharyngeal RT-PCR. The date of symptom onset was
145 considered Day zero. A second structured questionnaire (Questionnaire 2) was conducted 30
146 to 60 days after disease onset by telephone to document the RT-PCR result, acute symptoms,
147 and clinical outcome. Participants were classified as non-hospitalized or hospitalized in the
148 intensive care unit (ICU) or non-ICU). To avoid memory bias, questionnaires 1 and 2 were
149 applied in a short interval of time.

150 A third structured questionnaire was conducted 60 to 250 days after disease onset by
151 telephone to evaluate residual symptoms (Questionnaire 3). Questions included residual or
152 new symptoms: cough, fatigue, shortness of breath, headache, chest pain, dysphonia,
153 dysphagia, loss of appetite, loss of smell, loss of taste, myalgias, arthralgias, fever, and other
154 non-listed symptoms. Patients reporting suspected or confirmed re-infection were excluded
155 from the final analysis. A schematic diagram of the study is provided (**Additional file 1: Fig**
156 **S3**).

157

158 *Outcomes of interest*

159 Long COVID was defined according to the Centers for Disease Control and
160 Prevention classification [7]. Persistence of symptoms was defined as the presence of at least
161 one residual symptom > 1 month post disease onset. The list of residual symptoms presented
162 on the questionnaire was based on literature [8,9].

163 The European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) was conducted via
164 telephone to assess health dimensions: mobility, self-care, daily activities, pain/discomfort
165 and anxiety/depression. The EQ-visual analogue scale (VAS) was also conducted with 0
166 rated as worst health imaginable and 100 as the best imaginable health [10].

167

168 *Statistical analysis*

169 Categorical data were described using absolute values and percentages/frequencies.
170 Continuous data were described using mean (standard deviation, SD) and median
171 (interquartile range, IQR). The correlation matrix was constructed based on the frequency of
172 persistent symptoms reported by the patients. Multivariable logistic regression was performed
173 to explore risk factors related to long COVID, applying the odds ratios (OR; 95% CI).
174 Analyses were done in R (version 4.2.0) [26].

175

176 **RESULTS**

177 In total, 1,268 patients with suspected SARS-CoV-2 infection were recruited and
178 answered the first questionnaire 4 days (range of 3-5 days) post symptom onset. After
179 excluding cases outside the RT-PCR recommended window period, reported re-infection, or
180 those lost to follow-up, 814 (64.2%) patients were considered eligible for the analysis of
181 residual symptoms (**Fig. 1, Additional file 1: Fig. S3**). Questionnaires 2 and 3 were
182 conducted 40 (31-59) days and 102 (63-150) days post symptom onset, respectively. No
183 difference in sociodemographic data and frequency of positive RT-PCR were observed
184 between the included (n=814) and excluded (n=454) participants (**Additional file 1: Table**
185 **S1**). Among the included participants, 412 tested positive (COVID-19 group) and 402 tested
186 negative (non-COVID-19 group) for SARS-CoV-2. Demographic characteristics for the
187 COVID and non-COVID groups were as follows, respectively: a median age of 36 (IQR) and
188 34 (IQR) years, female gender of 55% and 64%, mild disease in 84% and 99% (**Table 1**).
189 More patients were hospitalized in the COVID-19 group compared to the non-COVID-19
190 group (15.9% vs 1.5%, respectively, **Table 1**). Follow-up time was 3.3 months for the
191 COVID group and 3.7 months for the non-COVID group (**Additional file 1: Fig. S4**).

192 After one month post disease onset, per the CDC definition for long COVID
193 (September 16, 2021), 122/412 (29.6%) individuals from the COVID group reported residual

194 symptoms and were classified as long COVID cases, while the remaining 290 individuals
195 were fully recovered. From the non-COVID group, residual symptoms were reported by only
196 24 (6%) individuals (**Table 1**). Among long COVID cases, 57 (13.2%) presented with more
197 than two residual symptoms.

198 Within the COVID group, fatigue (56, 13.7%), olfactory disorder (42, 9.9%), myalgia
199 (36, 8.7%), gustatory disorder (27, 6.6%), and headache (26, 6.1%) were the residual
200 symptoms most frequently reported (**Fig. 2**). These symptoms started mainly during the acute
201 phase. Other symptoms not reported during the acute phase, such as memory loss and hair
202 loss, were reported by the patients with long COVID (**Additional file 1: Table S2**).
203 Compared to those who recovered, the long COVID group had more women (63.1% vs.
204 52.1%) and older individuals [40 (32-51) vs. 35 (28-47) years] (**Table 2**). Hospitalization for
205 acute disease was comparable between long COVID (21/122, 17.2%) and recovered patients
206 (44/290, 15.2%).

207 The risk of long COVID increased with age and was significant for persons 50 years
208 of age or older (OR 2.44, 95% CI 1.29-4.66). Individuals with > five symptoms in the acute
209 phase (OR 3.15, 95% CI 1.37-8.55) and females (OR 1.55, 95% CI 0.99-2.44) were more
210 likely to develop long COVID (**Table 3**).

211 Co-occurrence of long COVID symptoms was also observed. Fatigue was reported by
212 at least 50% of those that complained of gustatory dysfunction, anorexia, dysphonia, chest
213 pain, headache, breathlessness, or myalgia. Moreover, olfactory dysfunction was reported by
214 80% of participants with gustatory dysfunction (**Additional file 1: Fig. S5**).

215 Finally, we have evaluated the impact of long COVID on the quality of life. The EQ-
216 5D-3L questionnaire was administered to 102 out of 122 patients. Fifty-seven patients
217 (55.8%) reported alteration in at least one dimension of QoL, and 41 patients (41.1%) had an
218 impact in the dimension of pain and depression (**Additional file 1: Table S3**).

219

220 **DISCUSSION**

221 We have followed RT-PCR positive and negative patients with COVID-like
222 symptoms from the first days post symptom onset to 63-150 days post symptom onset to
223 determine the prevalence of long COVID-19. Long COVID occurred in almost one-third of
224 test-positive cases, the majority with mild acute disease, compared to 6% of negative patients
225 with residual symptoms, supporting the association between SARS-CoV-2 infection and
226 residual symptoms. The risk of long COVID increased with age > 50 years old, female
227 gender, and the development of > five symptoms during the acute phase. Together these
228 findings demonstrate that residual symptoms after mild disease were mainly associated with
229 COVID-19 with well-defined demographic and clinical risk factors.

230 The proportion of patients with COVID-19 who developed long COVID has varied
231 from 7.5% to 89% [1, 2, 28, 29]. Most studies only included patients who tested positive for
232 SARS-CoV-2. One strength of our study is the inclusion of a comparator group of
233 symptomatic patients, recruited in the same time/location, who tested negative by SARS-
234 CoV-2 RT-PCR. Additionally, most symptoms investigated in the follow-up questionnaires
235 were evaluated at the time of recruitment, in a blinded manner, prior to the SARS-CoV-2 test
236 result. The inclusion of a control group is important considering that many residual
237 symptoms attributed to long COVID, such as fatigue and headache, are nonspecific and could
238 be triggered or aggravated by stress and psychosocial problems connected to the global health
239 crisis [11-13]. Indeed, we observed that non-confirmed COVID-19 cases reported similar
240 residual symptoms after acute illness, albeit at a much lower frequency. Few studies have
241 included a control group composed of symptomatic patients that tested negative for SARS-
242 CoV-2 [14, 30]. In a cohort of healthcare workers, olfactory disorders and hair loss were
243 related to long COVID while positive and negative cases both had similar frequencies of

244 exhaustion/burnout and fatigue [14]. In a population-based digital retrospective cohort
245 including outpatients and well-matched controls, 62 symptoms were associated with long
246 COVID [30]. The inclusion of a control group is even more valuable for hospitalized cases,
247 considering the increased risk of sequelae associated with iatrogenic procedures for treating
248 severe disease [15]. Together, these findings highlight the importance of including a control
249 group when determining the frequency of sequelae to avoid overestimating long COVID
250 cases.

251 We observed a similar proportion of long COVID in groups with mild and
252 moderate/severe disease [16,17]. We enrolled a small number of severe COVID-19 cases and
253 therefore could not conclude an association between disease severity and sequelae. Severe
254 COVID-19 increases the risk of long COVID by 1.2 to 8x among hospitalized cases
255 compared to those not hospitalized [18]. Nonetheless, the finding that long COVID occurs in
256 a significant proportion of individuals after mild disease highlights its potential impact on the
257 healthcare system, as COVID-19 variants and sub-variants continue to spread worldwide.

258 Fatigue was the most frequent sequelae and occurred isolated or associated with other
259 clinical manifestations. As previously reported [19], we also observed a vast impact of long
260 COVID on the quality of life. Although the mechanism is unknown, an exacerbation of the
261 immunological response and multisystemic involvement [20] seems to be involved. Studies
262 investigating the pathogenesis of long COVID are essential to improve treatment and
263 attenuate the impact.

264 Similar to previous studies [3, 9, 17, 21-23, 30], we found that long COVID was more
265 prevalent in women and could be attributed to a greater propensity for women to go to a
266 clinic [22]. Indeed, females represented 55% of the COVID group and 64% of the non-
267 COVID group in our study. Sex hormone differences in immune response [24] and
268 autoimmunity triggered by SARS-CoV-2 have been suggested to be involved in the disease

269 pathogenesis of long COVID [23]. Other studies have found that individuals with more
270 symptoms during the acute phase were at a higher risk for developing long COVID [9, 14].
271 There are conflicting results regarding age in the risk for developing long COVID. In a
272 cohort of healthcare workers in Switzerland, the majority of whom had mild disease, young
273 age was associated with a higher risk for developing long COVID [14], in contrast to our
274 findings. Additional prospective studies including multicenter cohorts with larger sample
275 sizes and older patients should be performed to evaluate if the risk for developing long
276 COVID differs among age groups, racial groups, and ethnicities. Prospective studies to
277 develop predictive models and algorithms should be performed for the early detection of long
278 COVID cases.

279 Long COVID has different definitions. We have used the CDC's definition for long
280 COVID (September 16, 2021), that includes persistence of symptoms after four weeks of the
281 onset of disease. Recently, a WHO-coordinated Delphi consensus established a period of
282 more than three months after COVID-19 onset for the case definition of long COVID [25]. In
283 our study, only 445 of the calls were performed three months after disease onset. By this
284 definition, long COVID was detected in 68/216 (31.5%) of our patients. Residual symptoms
285 were also observed in 17/229 (7.4%) of the non-COVID-19 patients. As observed in our
286 study, the prevalence of long COVID may vary between studies in the absence of a universal
287 consensus to define long COVID [4]. This impacts the estimation of the prevalence of long
288 COVID cases worldwide.

289 This study has some limitations. The loss to follow-up was around 36% of patients
290 and may have influenced the estimates of residual symptoms. Similar demographic and
291 clinical characteristics were observed among patients that were included and the ones that
292 were lost to follow-up. In addition, most participants were young, with mild disease, which
293 does not permit generalizing these findings to the elderly and those with severe disease.

294 Moreover, the participants were aware of their diagnosis of COVID-19 when questionnaire 3
295 was applied, which may have led to an overestimation of persistent symptoms. Finally, the
296 short time to follow-up did not allow for an analysis of the duration of long COVID.

297 **CONCLUSIONS**

298 Long COVID was detected in 29.6% of patients with mild COVID-19 disease, with
299 older age, female sex, and polysymptomatic acute disease as the main risk factors for
300 persistent symptoms. Estimating the long COVID prevalence is important for preparing the
301 healthcare system to assist and guide these patients. Further studies should be conducted to
302 evaluate the impact of different variants of SARS-CoV-2 on long COVID and the potential
303 impact of vaccines in reducing residual symptoms.

304

305 **LIST OF ABBREVIATIONS**

306 STROBE – Strengthening the Reporting of Observational Studies in Epidemiology

307 RT-PCR – Reverse Transcriptase Polymerase Chain Reaction

308 REDCap – Research Electronic Data Capture software

309 IGM/FIOCRUZ – Gonçalo Moniz Institute

310 ICU – Intensive Care Unit

311 SD – Standard Deviation

312 IQR – Interquartile Range

313

314 **DECLARATIONS**

315 **Ethics approval and consent to participate:** Informed consent was obtained from all
316 participants. The Ethics in Research Committee of the Gonçalo Moniz Research Center
317 approved this study (approval no. 4.315.319/202).

318 **Consent for publication:** Not applicable

319 **Availability of data and materials:** The dataset generated and/or analyzed during the
320 current study are not publicly available due to legal and ethical restrictions. Dataset are
321 available upon request.

322 **Funding:** This study was supported by MCTI/CNPq/FNDCT/MS/SCTIE/Decit (n° 07/2020)
323 MB-N, AB and VSB are research fellows from CNPq, the Brazilian National Research
324 Council. T.C-S. is a PhD student at the Post-Graduation Program in Health Sciences-UFBA,
325 which is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-
326 Brasil, finance code 001.

327 **Competing interests:** The authors do not have conflicts of interests to declare for this work.

328 **Authors' contributions:** A.B.C.C. and V.B structured the original draft. V.B. and C.B. were
329 responsible for conceptualization and methodology. A.P.B., G.L.S, A.C.A.A, M.Q.A.B,
330 N.R.S and A.B.C.C collected data from the patients. T.C.S made the formal analysis
331 statistics. A.M.P.B. and V.B. participated in the project administration and in the funding
332 acquisition. TCS, JD, ACB, LPGC, MBN, ABN, CGB substantively revised the manuscript.
333 All authors read and approved the final manuscript.

334 **Acknowledgements:** We wish to thank all patients who were willing to participate in the
335 study. In addition, we would like to thank Hospital Aeroporto and Municipal Health
336 Secretariats of Irecê and Campo Formoso for logistical support and to Roberta de Carvalho
337 Freitas for patient-related support.

338

339

340 **REFERENCES**

- 341 [1] Chen C, Hauptert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global
342 Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic
343 Review. *The Journal of Infectious Diseases*. 2022 Apr 16;jiac136.
- 344 [2] Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of
345 Persistent Symptoms Among Patients With COVID-19. *JAMA Network Open*. 2021 May
346 26;4(5):e2111417.
- 347 [3] Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for
348 characterizing long COVID. *Nature Medicine*. 2021 Jun 17;27(7):1129–30.
- 349 [4] Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al.
350 Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a
351 systematic review and meta-analysis. *Clinical Microbiology and Infection*. 2022 Feb;28(5).
- 352 [5] Kelly BD, Gulati G. Long COVID: the elephant in the room. *QJM: An International*
353 *Journal of Medicine*. 2021 Nov 26;115(1):5–6.
- 354 [6] Nagib W. Home [Internet]. Genomahcov - Fiocruz. Available from:
355 <http://www.genomahcov.fiocruz.br/>
- 356 [7] CDC. COVID-19 and Your Health [Internet]. Centers for Disease Control and Prevention.
357 2020. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/>
- 358 [8] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A,
359 et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.
360 *Scientific Reports* [Internet]. 2021 Aug 9 [cited 2021 Aug 16];11(1):16144. Available from:
361 <https://www.nature.com/articles/s41598-021-95565-8>
- 362 [9] Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al.
363 Attributes and predictors of long COVID. *Nature Medicine* [Internet]. 2021 Apr 1 [cited 2021
364 May 8];27(4):626–31. Available from: <https://www.nature.com/articles/s41591-021-01292-y>

- 365 [10] EuroQol. EQ-5D User Guides – EQ-5D [Internet]. EQ-5D User Guides. 2022 [cited
366 2022 Sep 17]. Available from: <https://euroqol.org/publications/user-guides>
- 367 [11] Bartoszek A, Walkowiak D, Bartoszek A, Kardas G. Mental Well-Being (Depression,
368 Loneliness, Insomnia, Daily Life Fatigue) during COVID-19 Related Home-Confinement—
369 A Study from Poland. *International Journal of Environmental Research and Public Health*.
370 2020 Oct 12;17(20):7417.
- 371 [12] Usher K, Bhullar N, Jackson D. Life in the pandemic: Social isolation and mental health.
372 *Journal of Clinical Nursing*. 2020 Apr 6;29(15-16).
- 373 [13] Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The
374 Psychological Impact of Quarantine and How to Reduce it: Rapid Review of the Evidence.
375 *The Lancet*. 2020 Feb 26;395(10227):912–20.
- 376 [14] Strahm C, Seneghini M, Güsewell S, Egger T, Leal O, Brucher A, et al. Symptoms
377 compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection
378 – results of a prospective multicenter cohort. *Clinical Infectious Diseases*. 2022 Jan 28;75(1).
- 379 [15] Evans RA, Leavy OC, Richardson M, Elneima O, McCauley HJC, Shikotra A, et al.
380 Clinical characteristics with inflammation profiling of long COVID and association with 1-
381 year recovery following hospitalisation in the UK: a prospective observational study. *The*
382 *Lancet Respiratory Medicine*. 2022 Apr;10(8).
- 383 [16] Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent
384 fatigue following SARS-CoV-2 infection is common and independent of severity of initial
385 infection. Madeddu G, editor. *PLOS ONE*. 2020 Nov 9;15(11):e0240784.
- 386 [17] Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, et al. Female gender
387 is associated with “long COVID” syndrome: a prospective cohort study. *Clinical*

388 Microbiology and Infection. 2021 Nov;28(4).

389 [18] Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-
390 COVID-19 symptoms 6 months after acute infection among hospitalized and non-
391 hospitalized patients. *Clinical Microbiology and Infection*. 2021 Oct;27(10):1507–13.

392 [19] Kim Y, Kim S-W, Chang H-H, Kwon KT, Hwang S, Bae S. One Year Follow-Up of
393 COVID-19 Related Symptoms and Patient Quality of Life: A Prospective Cohort Study.
394 *Yonsei Medical Journal*. 2022;63(6):499.

395 [20] Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A. COVID-
396 19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System.
397 *World Neurosurgery*. 2020 Aug;140:49–53.

398 [21] Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, á Steig B, Gaini S, et al.
399 Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Patients.
400 *Clinical Infectious Diseases*. 2020 Nov 30;73(11).

401 [22] Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-
402 COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective
403 cohort study. *The Lancet Regional Health – Europe* [Internet]. 2021 Jul 1 [cited 2021 Nov
404 5];6. Available from: [https://www.thelancet.com/journals/lanep/article/PIIS2666-
405 7762\(21\)00099-5/fulltext#coronavirus-linkback-header](https://www.thelancet.com/journals/lanep/article/PIIS2666-7762(21)00099-5/fulltext#coronavirus-linkback-header)

406 [23] Seeßle J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent
407 symptoms in adult patients one year after COVID-19: a prospective cohort study. *Clinical
408 Infectious Diseases*. 2021 Jul 5;74(7).

409 [24] Stewart S, Newson L, Briggs TA, Grammatopoulos D, Young L, Gill P. Long COVID
410 risk - a signal to address sex hormones and women's health. *The Lancet Regional Health -*

411 Europe. 2021 Nov;11:100242.

412 [25] Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-
413 COVID-19 condition by a Delphi consensus. The Lancet Infectious Diseases. 2021 Dec
414 21;22(4).

415 [26] R Core Team. R: The R Project for Statistical Computing [Internet]. R-project.org. 2019.
416 Available from: <https://www.r-project.org/>

417 [27] Biorender. BioRender [Internet]. Home. biorender-marketing-site; 2019. Available from:
418 <https://biorender.com>

419 [28] Office for National Statistics. Statements and letters - Office for National Statistics
420 [Internet]. www.ons.gov.uk. 2020 [cited 2022 Sep 17]. Available from:
421 <https://www.ons.gov.uk/news/statementsandletters/>

422 [29] CDC. Nearly One in Five American Adults Who Have Had COVID-19 Still Have “Long
423 COVID” [Internet]. www.cdc.gov. 2022 [cited 2022 Sep 17]. Available from:
424 https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm#:~:text=Over
425 [all%2C%201%20in%2013%20adults](https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm#:~:text=Over)

426 [30] Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et
427 al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nature Medicine.
428 2022 Aug 1;28(8):1706–14.

429

430 **TABLES**

431 **Table 1:** Clinical, sociodemographic characteristics and frequency of residual symptoms for
432 COVID-19 and non-COVID-19 cases.

Characteristic ¹	COVID-19 cases n = 412	Non-COVID-19 cases n = 402
Age	36 (28-48)	34(25-43)
Age group		
15-29	126 (30.6%)	167 (41.5%)
30-39	123 (29.9%)	106 (26.4%)
40-49	75 (18.2%)	82 (20.4%)
>50	88 (21.4%)	47 (11.7%)
Female sex	228 (55.3%)	259 (64.4%)
Body mass index (BMI)	27 (23.5-29.8)	26.1 (23.5-29.1)
Number of acute symptoms	11 (8-14)	10 (7-13)
Comorbidities	148 (35.9%)	131 (32.5%)
Diabetes mellitus	12 (11.0%)	11 (2.7%)
Respiratory allergy	95 (23.3%)	126 (31.3%)
Obesity	102 (24.8%)	86 (21.4%)
Normal	310 (75.2%)	316 (78.6%)
Obese (BMI 30-34)	21 (5.1%)	17 (4.2%)
Overweight (BMI 35-39)	79 (19.2%)	67 (16.7%)

Extremely obese (BMI >40)	2 (0.5%)	2 (0.5%)
Number of comorbidities		
1	101 (24.5%)	90 (22.4%)
>1	47 (11.4%)	41 (10.2%)
Type of Hospitalization		
Outpatient (mild)	346 (84.2%)	395 (98.5%)
Hospitalization non-ICU (moderate)	59 (14.4%)	6 (1.5%)
Hospitalization ICU (severe)	6 (1.5%)	0 (0%)
At least one residual symptom		
> 1 month after disease onset	122 (29.6%)	24 (5.8%)
Number of residual symptoms (median)		
1	65 (15.8%)	9 (2.2%)
>1	57 (13.2%)	13 (5.4%)
Call Time Persistent Symptoms	3.35 (2.1-5.2)	3.65 (2.1-4.9)

434 ¹n(%) or Median (IQR)

435

436 **Table 2:** Clinical, sociodemographic characteristics and frequency of residual symptoms for
437 COVID cases with or without sequelae.

Characteristic ¹	No Sequelae n=290	Sequelae n=122
Age	35 (28, 47)	40 (32, 51)
Age group		
15-29	99 (34.1%)	27 (22.1%)
30-39	85 (29.3%)	38 (31.1%)
40-49	51 (17.9%)	24 (19.7%)
>50	55 (19.0%)	33 (27.0%)
Female sex	151 (52.1%)	77 (63.1%)
BMI	26.9 (23.5, 29.7)	27.2 (23.8, 30.1)
Number of acute symptoms	11 (7, 14)	12 (9, 15)
Comorbidities	101 (34.8%)	47 (38.5%)
Diabetes mellitus	6 (2.1%)	6 (2.1%)
Respiratory allergy	63 (21.9%)	32 (26.2%)
Obesity	70 (24.1%)	32 (26.2%)
Obese (BMI 30-34)	12 (4.1%)	9 (7.4%)
Overweight (BMI 35-39)	57 (19.7%)	22 (18.0%)

Extremely obese (BMI >40)	1 (0.3%)	1 (0.3%)
---------------------------	----------	----------

Number of comorbidities		
--------------------------------	--	--

1	75 (25.9%)	26 (21.3%)
---	------------	------------

>1	26 (9.0%)	21 (17.2%)
----	-----------	------------

Time of disease onset	3.30 (2.00, 5.10)	3.75 (2.12, 5.55)
------------------------------	-------------------	-------------------

Hospitalization	44 (15.2%)	21 (17.2%)
------------------------	------------	------------

1. n(%) or Median (IQR)

438

439

440

441 **Table 3.** Multivariable analysis of odds ratio (lower and upper confidence intervals) for
442 presenting long COVID symptoms.

	OR	LCI*	UCI*	P value
Age group (reference 14-29 years)				
30-39	1.71	0.95	3.12	0.078
40-49	2.04	1.02	4.10	0.045
≥ 50	2.44	1.29	4.66	0.006
Female sex	1.55	0.99	2.44	0.055
> 5 acute symptoms	3.15	1.37	8.55	0.012


*LCI and UCI - lower and upper confidence intervals, respectively

443

444 **FIGURES**

445 **Fig 1.** Flowchart of the study population.

446




447

448

449

450 **Fig. 2:** Frequency of acute and residual symptoms for COVID-19 and non-COVID-19 cases.



451

452